Clonal Hematopoiesis of Immunological Significance

Sponsor
Assistance Publique - Hôpitaux de Paris
Study ID
NCT05969821
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Autoimmune Diseases
  • Autoinflammatory Diseases
  • Clonal Hematopoiesis of Indeterminate Potential
  • Hematologic Diseases
  • Hematopoiesis Clonal
  • Immune System Diseases
  • Inflammation
  • Leukemia
  • Leukemia Myelomonocytic Chronic
  • Lymphoma
  • Lymphoproliferative Disorders
  • Monoclonal Gammopathy of Undetermined Significance
  • Myelodysplastic Syndromes
  • Myelodysplastic-Myeloproliferative Diseases
  • Myeloproliferative Disorders
  • Vexas Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • observational cohort study — OTHER
    observational cohort study

Study Details

Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.

Key Dates

First listed
Aug 1, 2023
Start date
Apr 30, 2026
Status verified
Mar 2026
Primary completion
Apr 30, 2036
Completion
Sep 30, 2045

Study Design

Enrollment
5,000 participants (estimated)

Arms

  • Arm: Dysimmune manifestations with or without clonal hematopoiesis
    Dysimmune manifestations with or without clonal hematopoiesis

Primary Outcome Measure

Incidence of dysimmune manifestations associated with hematological disorders [ Time Frame: Baseline ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies